ARGX
argenx NV ADR
NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY
$782.17
+5.82% today
Updated 2026-06-05
Market cap
$55.09B
P/E ratio
39.11
P/S ratio
11.62x
EPS (TTM)
$22.54
Dividend yield
—
52W range
$510 – $935
Volume
0.3M
argenx NV ADR (ARGX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed ARGX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$782.17
Today
Analyst consensus
$1,018.00
+30.15% · 12M
2030 Base
$1,175.66
+50.31% future
NPV today
$757.64
@ 10% WACC
24 analysts:
20 Buy4 Hold0 Sell
Management guidance
CEO Karen Massey reaffirmed Vision 2030 targeting: (1) 50,000 patients treated globally, (2) 10 labeled indications for VYVGART and pipeline, (3) 5 pipeline candidates advanced to Phase 3. Company achieved $4.25B revenue in 2025 (+88.6% YoY) and $1.31B in Q1 2026 (+62.7% YoY). Management guidance implies sustained high-double-digit to mid-40% annual growth through 2030 driven by VYVGART label expansion (serotypes now approved for all gMG patients), geographic expansion, and pipeline advancement.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
ARGX · argenx NV ADR · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$360.69
NPV today: $232.44
Base case (2030)
$1,175.66
NPV today: $757.64
Bull case (2030)
$2,805.59
NPV today: $1,808.02
WallStSmart.com
ARGX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $4.2B | $6.1B | $8.7B | $11.3B | $14.2B | $17.2B |
| Revenue growth | 89.6% | 44.8% | 40.8% | 31.1% | 25.0% | 21.3% |
| Net margin | — | 27.6% | 27.9% | 29.0% | 29.6% | 30.2% |
| EPS | $16.76 | $27.11 | $38.50 | $52.25 | $66.50 | $82.10 |
| Diluted shares | — | 62M | 63M | 63M | 63M | 63M |
| Net debt | — | $3.08B | $7.40B | $13.07B | $20.16B | $28.76B |
| P/S multiple | — | 6.0x | 6.0x | 6.0x | 6.0x | 6.0x |
| Implied price (base) | — | $540.75 | $709.84 | $873.37 | $1,028.38 | $1,175.66 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $17.2B | $17.2B | $17.2B |
| P/S multiple | 3.0x | 6.0x | 12.0x |
| Diluted shares | 63M | 63M | 63M |
| Net debt | $28.76B | $28.76B | $28.76B |
| Implied P/E † | 4x | 14x | 34x |
| 2030 Price | $360.69 | $1,175.66 | $2,805.59 |
| NPV @ 10% | $232.44 | $757.64 | $1,808.02 |
† Implied P/E: Multiples remain elevated across all three scenarios because ARGX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $1,175.66 base case
ARGX catalysts and risks
Growth catalysts
+ VYVGART label expansion to all adult gMG patients (FDA approved May 2026) — unlocks all-comers market, eliminates serotype testing barrier
+ Subcutaneous VYVGART Hytrulo formulation adoption — increases patient convenience, expands addressable population by estimated 30-40%
+ Pipeline progression: empasiprubart (myositis, MMN) Phase 3 data readouts 2026-2027; 10-indication Vision 2030 roadmap with 5+ Phase 3 candidates de-risks single-asset dependency
+ Geographic expansion: U.S. commercial ramp (largest market, 60%+ of gMG patients); European rollout acceleration; emerging markets penetration
+ Market share gains in IgG-mediated rare autoimmune diseases — TAM expands beyond gMG/CIDP to myositis, MMN, AChR-seronegative myasthenia, other indications
Key risks
- VYVGART competition: FcRn inhibitor landscape expanding (Rozanolixizumab, next-gen entrants); pricing pressure in mature markets; formulary/reimbursement restrictions
- Pipeline execution risk: Phase 3 failures for empasiprubart or other candidates would force portfolio contraction and slow outer-year growth targets
- Manufacturing/supply chain constraints: subcutaneous formulation scale-up complexity; any production disruption throttles revenue upside
- Regulatory setbacks: EMA approval delays; FDA label expansion limitations; safety signals in ongoing trials (myositis, MMN)
- Patent cliff exposure: VYVGART exclusivity dependent on label maintenance; competing FcRn inhibitors eroding market share post-2028
- Valuation multiple compression: Biotech sector rotation or profit-taking could reduce forward P/E from 29.7x (2026E) toward 18-22x, pressuring stock despite strong revenue growth
Methodology · argenx NV ADR 2030 stock forecast model
argenx NV ADR 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 24 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for ARGX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($28.76B by 2030) |
| 3. Time value | NPV calculated using 10% WACC (sector fallback) |
| 4. Multiple framework | P/S compresses with scale: bear 3.0x / base 6.0x / bull 12.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
ARGX price target FAQ
What is the ARGX price target for 2030?
WallStSmart's argenx NV ADR 2030 base case is $1,175.66 per share, with a bull case of $2,805.59 and bear case of $360.69. The NPV of the base case discounted to today at 10% WACC is $757.64.
How is the argenx NV ADR 2030 stock forecast calculated?
The ARGX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the ARGX price target account for dilution?
argenx NV ADR is projected to grow diluted share count from 62M to 63M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on ARGX stock?
24 analysts cover ARGX with an average 12-month price target of $1,018.00. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.